1,721,052 research outputs found
Vascular Endothelial Growth Factor (VEGF) serum concentration: putative predictive biomarker for Electroconvulsive Therapy in depressed patients.
No full textEffectiveness of cognitive behavioral therapy in the treatment of fibromyalgia syndrome: a meta-analytic literature review
No full textFibromyalgia (FM) is a chronic disorder caused by a dysfunction of central nervous system sensitization. This syndrome is characterized by widespread pain and diffuse tenderness, but often also presents fatigue, sleep disturbances, and a whole range of symptoms such as morning stiffness, decreased physical function and dyscognition. FM is usually treated with pharmacological and non-pharmacological treatments. The non-pharmacological interventions include cognitive behavioral therapy (CBT), physiotherapy, acupuncture and patient education programs. In order to evaluate the efficacy of CBT and compare it with other non-pharmacological treatments, we performed a review of the meta-analytic literature. We evaluated the methodological quality of publications found by following the recommendations of the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement. Data showed that CBT does not provide better results than other non-pharmacological treatments on outcomes of pain, fatigue, sleep disturbance and quality of life, at either a short or long-term evaluation. On the contrary, CBT seems to be more effective on symptoms of depression for a short period, whereas it considerably improves the pain self-management and reduces the number of visits to the doctor. The data currently available indicate that cost-effectiveness studies could help us to understand whether the reduction in the number of visits to the doctor could balance the cost of CBT to the health public system
[Effectiveness of cognitive-associated with behavioral therapy psychopharmacological depression. Literature review meta-analyses]
No full textThe main focus is to analyze meta-analyses literature inherent the efficacy of cognitive behavioural therapy (CBT) with pharmacological therapy in the treatment of depression in adults rather than pharmacological therapy alone
Lateralized readiness potential elicited by undetected visual stimuli
No full textVisual stimuli undetected by normal subjects as a result of masking procedures can nonetheless activate response preparation in motor areas and yield a motor response. An unanswered question is whether the same holds for undetected subliminal stimuli that are not responded to. To answer this question, in this study normal subjects were tested on a simple visual reaction time task with stimuli above, at, or below the psychophysical threshold while the lateralized readiness potential (LRP), i.e. an electrophysiological correlate of premotor activation in the primary motor cortex, was computed. We found a reliable LRP not only for suprathreshold stimuli but also for subthreshold stimuli to which subjects did not respond. The main thrust of this study is that it provides evidence that activation of the motor cortex occurs even with subthreshold visual stimuli and without an overt response
ELECTROPHYSIOLOGICAL EVIDENCE OF MOTOR PREPARATION IN RESPONSE TO UNDETECTED VISUAL STIMULI.
No full textGenomic restricted maximum likelihood (GREML) analysis to estimate the heritability of response/resistance in major depressive disorder (MDD)
Full text linkIntroduction:
MDD is the leading cause of disability worldwide and lack of response to treatment is reported in ~30% of subjects. Pharmacogenomics studies performed so far failed to identify single SNPs with a replicable effect on anti-depressants response (AD). Instead of focusing on single SNPs, our study aims to evaluate the aggregated contribution on AD response for genome-wide variants and currently known genetic variants from pharmGKB, the main catalog of known pharmacogenetic variations.
Methods:
We used GREML-LDMS (LD- and MAF-Stratified) analysis to estimate the heritability of Citalopram response and treatment-resistant status (TRD) in MDD patients from the STAR*D anti-depressants pharmacogenetic trial. We estimated the overall genetic contribution for genome-wide SNPs present in the dataset, as well as for different groups of candidate SNPs from pharmGKB.
Results:
We detected a small, but significant, proportion of variance explained by SNPs associated with Citalopram in pharmGKB when including those with the lower level of evidence (V(G)/Vp 0.04; SE 0.02; p 2.23E-05). High heritability emerged when considering genome-wide SNPs for Citalopram response (V(G)/Vp 0.76; SE 0.23; p 0.026), Citalopram symptoms improvement (V(G)/Vp 0.82; SE 0.22; p 0.046) and TRD phenotype (V(G)/Vp 0.81; SE 0.24; p 0.022).
Conclusions:
Our preliminary results confirm a little effect of single SNPs and suggest that taking into account the overall genetic variability of pharmGKB AD-related SNPs and, even more, of genome-wide SNPs could improve antidepressant response/resistance prediction
No Less No More: The number of electroconvulsive therapy (ECT) trials for symptomatology improvement.
No full text
The influence of psychiatric screening in healthy populations selection: a new study and meta-analysis of functional 5-HTTLPR and rs25531 polymorphisms and anxiety-related personality traits.
No full text- …
